Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7371057 | 0.97 | BRD4 (0.44) | BRD4MAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5236831 | 0.84 | L3MBTL1 (0.42) | ALDH1A1KDM4EHSD17B10MAPTKMT2A | |
| SCHEMBL6773220 | 0.78 | MAOB (0.42) | MAOBALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL16931455 | 0.77 | MAOB (0.41) | MAOBALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL760652 | 0.77 | NAMPT (0.42) | MAOBALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL7364520 | 0.76 | MAOB (0.40) | MAOBALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL5444456 | 0.75 | NAMPT (0.41) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5189062 | 0.75 | NAMPT (0.41) | ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL16931119 | 0.74 | MAOB (0.41) | BRD4MAOBALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19461352 | 0.74 | MAOB (0.46) | BRD4MAOBALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1019372-B1 | FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
| EP-0725775-B1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5750702-A | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1998002420-A9 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | — | 1998-04-23 | — | — | WO | disclosed |
| US-5723462-A | SLEEP AND SEIZURE DISORDERS; COGNITION ACTIVATORS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0825193-A1 | Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998002420-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002433-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997026243-A1 | NOVEL FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-07-24 | — | — | WO | disclosed |
| US-5608079-A | MEMORY ENHANCEMENT IN BRAINS | NEUROGEN CORPORATION (US) | 1997-03-04 | — | — | US | disclosed |
| US-5484944-A | ANXIETY, SLEEP, MEMORY | NEUROGEN CORPORATION (US) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | BRD4 1606/4885MAOB 4429/4885ALDH1A1 4131/4885 |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | BRD4 1812/4885MAOB 290/4885ALDH1A1 2117/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | BRD4 2877/4885MAOB 1122/4885ALDH1A1 1595/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | BRD4 2877/4885MAOB 1122/4885ALDH1A1 1595/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | BRD4 1606/4885MAOB 4429/4885ALDH1A1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.